{"transactions":[{"id":1731760,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":2,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2023-11-22T18:28:27.000Z","date":"2023-11-20","kind":"other","planned":false,"acquired":true,"shares":585366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The common stock warrants expire on November 20, 2028, and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta R2. Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Vedanta R2. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":585366,"derivative":{"exercise_price":5,"expiration_date":"2028-11-20","underlying":"Common Stock","underlying_shares":585366},"source":{"system":"sec-edgar","filing":"0001493152-23-042540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000149315223042540/ownership.xml","form_type":"4"}},{"id":1731759,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":2,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2023-11-22T18:28:27.000Z","date":"2023-11-20","kind":"other","planned":false,"acquired":true,"shares":585366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta R2. Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Vedanta R2. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":585366,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":585366},"source":{"system":"sec-edgar","filing":"0001493152-23-042540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000149315223042540/ownership.xml","form_type":"4"}},{"id":2161581,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":513834,"price":0.0001,"value":51.3834,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The common stock warrants expire on September 8, 2027 and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":513834,"derivative":{"exercise_price":2.4,"expiration_date":"2027-09-08","underlying":"Common Stock","underlying_shares":513834},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2161580,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":869565,"price":0.0001,"value":86.9565,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The common stock warrants expire on September 8, 2027 and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":869565,"derivative":{"exercise_price":2.4,"expiration_date":"2027-09-08","underlying":"Common Stock","underlying_shares":869565},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2161579,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":513834,"price":2.5299,"value":1299948.6366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":513834,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":513834},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2161578,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":869565,"price":2.5299,"value":2199912.4935,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":869565,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":869565},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2684388,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":399000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":399000,"derivative":{"exercise_price":4.125,"exercise_date":"2021-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":299250},"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2684387,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":931000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":931000,"derivative":{"exercise_price":4.125,"exercise_date":"2021-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":698250},"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2684386,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":399000,"price":3.75,"value":1496250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":399000,"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2684385,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":931000,"price":3.75,"value":3491250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":931000,"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}}]}